Top

Published in:

18-12-2024 | Lymphoma | Research

Clinicopathological risk factors for prognosis and therapeutic response of primary central nervous system lymphoma in China: a single-center retrospective analysis of 118 cases

Authors: Ling Duan, Wenhui Guo, Shuo Yin, Gehong Dong, Wenbin Li, Feng Chen

Published in: Annals of Hematology | Issue 1/2025

Abstract

To investigate the prognostic significance of clinicopathological factors in patients with primary central nervous system lymphoma (PCNSL) in a single center. Patients newly diagnosed with PCNSL at our center were recruited between January 2019 and March 2023. Baseline demographic and clinicopathological data were collected retrospectively. The Kaplan–Meier method and Cox regression analysis were performed for survival analyses. A total of 118 patients were enrolled. The median age was 64 (IQR, 54–68). The median progression-free survival (PFS) and overall survival (OS) were 12.70 (95%CI, 9.73–23.30) months and 36.87 (95%CI, 25.57-NR) months, respectively. KPS < 70 and ECOG ≥ 3 were significantly associated with worse PFS and OS. High International Extranodal Lymphoma Study Group (IELSG) score (IELSG 4–5) and high-risk Memorial Sloan-Kettering Cancer Center (MSKCC) score were also adverse factors for PFS and OS. BTK inhibitors (BTKi) therapy (HR 0.39, 95% CI, 0.18–0.86, p = 0.020) and consolidation therapy (HR 0.19, 95% CI, 0.06–0.64, p = 0.007) were confirmed as independent favorable factors for OS. A high NK lymphocyte proportion was associated with worse OS (p = 0.008). Patients in the high NK lymphocyte group experienced a higher rate of primary tumor resistance (57.14%) than the low NK lymphocyte group (33.33%). KPS < 70, ECOG ≥ 3, IELSG 4–5, and high-risk MSKCC score are adverse factors for PFS and OS. Importantly, BTKi therapy and consolidation therapy are independent favorable factors for OS. Peripheral lymphocyte immunophenotyping could be a potential predictive indicator for prognosis and therapeutic response in PCNSL.

Available only for authorised users

Villano JL, Koshy M, Shaikh H, Dolecek TA, McCarthy BJ (2011) Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. Br J Cancer 105:1414–1418. https://doi.org/10.1038/bjc.2011.357CrossRefPubMedPubMedCentral

Ostrom QT, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS (2017) CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014. Neuro-oncology 19 https://doi.org/10.1093/neuonc/nox158

Mendez JS, Ostrom QT, Gittleman H, Kruchko C, DeAngelis LM, Barnholtz-Sloan JS, Grommes C (2018) The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades. Neurooncology 20:687–694. https://doi.org/10.1093/neuonc/nox187CrossRef

Shiels MS, Pfeiffer RM, Besson C, Clarke CA, Morton LM, Nogueira L, Pawlish K, Yanik EL, Suneja G, Engels EA (2016) Trends in primary central nervous system lymphoma incidence and survival in the U.S. Br J Haematol 174:417–424. https://doi.org/10.1111/bjh.14073CrossRefPubMedPubMedCentral

Radke J, Ishaque N, Koll R, Gu Z, Schumann E, Sieverling L, Uhrig S, Hübschmann D, Toprak UH, López C, Hostench XP, Borgoni S, Juraeva D, Pritsch F, Paramasivam N, Balasubramanian GP, Schlesner M, Sahay S, Weniger M, Pehl D, Radbruch H, Osterloh A, Korfel A, Misch M, Onken J, Faust K, Vajkoczy P, Moskopp D, Wang Y, Jödicke A, Trümper L, Anagnostopoulos I, Lenze D, Küppers R, Hummel M, Schmitt CA, Wiestler OD, Wolf S, Unterberg A, Eils R, Herold-Mende C, Brors B, Siebert R, Wiemann S, Heppner FL (2022) The genomic and transcriptional landscape of primary central nervous system lymphoma. Nat Commun 13:2558. https://doi.org/10.1038/s41467-022-30050-yCrossRefPubMedPubMedCentral

Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Müller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, Falini B, Banham AH, Rosenwald A, Staudt LM, Connors JM, Armitage JO, Chan WC (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275–282CrossRefPubMed

Houillier C, Soussain C, Ghesquières H, Soubeyran P, Chinot O, Taillandier L, Lamy T, Choquet S, Ahle G, Damaj G, Agapé P, Moluçon-Chabrot C, Amiel A, Delwail V, Fabbro M, Jardin F, Chauchet A, Moles-Moreau M-P, Morschhauser F, Casasnovas O, Gressin R, Fornecker L-M, Abraham J, Marolleau J-P, Tempescul A, Campello C, Colin P, Tamburini J, Laribi K, Serrier C, Haioun C, Chebrek S, Schmitt A, Blonski M, Houot R, Boyle E, Bay J-O, Oberic L, Tabouret E, Waultier A, Martin-Duverneuil N, Touitou V, Cassoux N, Kas A, Mokhtari K, Charlotte F, Alentorn A, Feuvret L, Le Garff-Tavernier M, Costopoulos M, Mathon B, Peyre M, Delgadillo D, Douzane H, Genet D, Aidaoui B, Hoang-Xuan K, Gyan E (2020) Management and outcome of primary CNS lymphoma in the modern era: An LOC network study. Neurology 94:e1027–e1039. https://doi.org/10.1212/WNL.0000000000008900CrossRefPubMedPubMedCentral

Houillier C, Dureau S, Taillandier L, Houot R, Chinot O, Moluçon-Chabrot C, Schmitt A, Gressin R, Choquet S, Damaj G, Peyrade F, Abraham J, Delwail V, Gyan E, Sanhes L, Cornillon J, Garidi R, Delmer A, Al Jijakli A, Morel P, Waultier A, Paillassa J, Chauchet A, Gastinne T, Laadhari M, Plissonnier A-S, Feuvret L, Cassoux N, Touitou V, Ricard D, Hoang-Xuan K, Soussain C (2022) Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients Age 60 Years and Younger: Long-Term Results of the Randomized Phase II PRECIS Study. J Clin Oncol 40:3692–3698. https://doi.org/10.1200/JCO.22.00491CrossRefPubMed

Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS (2015) CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008–2012. Neurooncology 17(Suppl 4). https://doi.org/10.1093/neuonc/nov189

10.

Tang D, Chen Y, Shi Y, Tao H, Tao S, Zhang Q, Ding B, He Z, Yu L, Wang C (2022) Epidemiologic Characteristics, Prognostic Factors, and Treatment Outcomes in Primary Central Nervous System Lymphoma: A SEER-Based Study. Front Oncol 12:817043. https://doi.org/10.3389/fonc.2022.817043CrossRefPubMedPubMedCentral

11.

Langner-Lemercier S, Houillier C, Soussain C, Ghesquières H, Chinot O, Taillandier L, Soubeyran P, Lamy T, Morschhauser F, Benouaich-Amiel A, Ahle G, Moles-Moreau M-P, Moluçon-Chabrot C, Bourquard P, Damaj G, Jardin F, Larrieu D, Gyan E, Gressin R, Jaccard A, Choquet S, Brion A, Casasnovas O, Colin P, Reman O, Tempescul A, Marolleau J-P, Fabbro M, Naudet F, Hoang-Xuan K, Houot R (2016) Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network. Neurooncology 18:1297–1303. https://doi.org/10.1093/neuonc/now033CrossRef

12.

Ferreri AJM, Blay J-Y, Reni M, Pasini F, Spina M, Ambrosetti A, Calderoni A, Rossi A, Vavassori V, Conconi A, Devizzi L, Berger F, Ponzoni M, Borisch B, Tinguely M, Cerati M, Milani M, Orvieto E, Sanchez J, Chevreau C, Dell’Oro S, Zucca E, Cavalli F (2003) Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol 21:266–272CrossRefPubMed

13.

Abrey LE, Ben-Porat L, Panageas KS, Yahalom J, Berkey B, Curran W, Schultz C, Leibel S, Nelson D, Mehta M, DeAngelis LM (2006) Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol 24:5711–5715CrossRefPubMed

14.

Wieduwilt MJ, Valles F, Issa S, Behler CM, Hwang J, McDermott M, Treseler P, O’Brien J, Shuman MA, Cha S, Damon LE, Rubenstein JL (2012) Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI. Clin Cancer Res 18:1146–1155. https://doi.org/10.1158/1078-0432.CCR-11-0625CrossRefPubMedPubMedCentral

15.

Schorb E, Kasenda B, Atta J, Kaun S, Morgner A, Hess G, Elter T, von Bubnoff N, Dreyling M, Ringhoffer M, Krause SW, Derigs G, Klimm B, Niemann D, Fritsch K, Finke J, Illerhaus G (2013) Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation. Haematologica 98:765–770. https://doi.org/10.3324/haematol.2012.076075CrossRefPubMedPubMedCentral

16.

Abrey LE, Batchelor TT, Ferreri AJM, Gospodarowicz M, Pulczynski EJ, Zucca E, Smith JR, Korfel A, Soussain C, DeAngelis LM, Neuwelt EA, O’Neill BP, Thiel E, Shenkier T, Graus F, van den Bent M, Seymour JF, Poortmans P, Armitage JO, Cavalli F (2005) Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 23:5034–5043

17.

Ahn Y, Ahn HJ, Yoon DH, Hong JY, Yoo C, Kim S, Huh J, Suh C (2017) Primary central nervous system lymphoma: a new prognostic model for patients with diffuse large B-cell histology. Blood Res 52:285–292. https://doi.org/10.5045/br.2017.52.4.285CrossRefPubMedPubMedCentral

18.

Deng X, Xu X, Lin D, Zhang X, Yu L, Sheng H, Yin B, Zhang N, Lin J (2020) Real-World Impact of Surgical Excision on Overall Survival in Primary Central Nervous System Lymphoma. Front Oncol 10:131. https://doi.org/10.3389/fonc.2020.00131CrossRefPubMedPubMedCentral

19.

Kawaguchi A, Iwadate Y, Komohara Y, Sano M, Kajiwara K, Yajima N, Tsuchiya N, Homma J, Aoki H, Kobayashi T, Sakai Y, Hondoh H, Fujii Y, Kakuma T, Yamanaka R (2012) Gene expression signature-based prognostic risk score in patients with primary central nervous system lymphoma. Clin Cancer Res 18:5672–5681. https://doi.org/10.1158/1078-0432.CCR-12-0596CrossRefPubMed

20.

Hatzl S, Posch F, Deutsch A, Beham-Schmid C, Stöger H, Greinix H, Pichler M, Neumeister P, Prochazka KT (2020) Immunohistochemistry for c-myc and bcl-2 overexpression improves risk stratification in primary central nervous system lymphoma. Hematol Oncol 38:277–283. https://doi.org/10.1002/hon.2727CrossRefPubMedPubMedCentral

21.

Liu CJ, Lin SY, Yang CF, Yeh CM, Kuan AS, Wang HY, Tsai CK, Gau JP, Hsiao LT, Chen PM, Liu YC, Hong YC, Ko PS, Liu JH, Lin CH (2020) A new prognostic score for disease progression and mortality in patients with newly diagnosed primary CNS lymphoma. Cancer Med 9:2134–2145. https://doi.org/10.1002/cam4.2872CrossRefPubMedPubMedCentral

22.

Jahr G, Broi MD, Holte H, Beiske K, Meling TR (2018) Evaluation of Memorial Sloan-Kettering Cancer Center and International Extranodal Lymphoma Study Group prognostic scoring systems to predict Overall Survival in intracranial Primary CNS lymphoma. Brain Behav 8:e00928. https://doi.org/10.1002/brb3.928CrossRefPubMedPubMedCentral

23.

Welch MR, Omuro A, Deangelis LM (2012) Outcomes of the oldest patients with primary CNS lymphoma treated at Memorial Sloan-Kettering Cancer Center. Neurooncology 14:1304–1311

24.

Bessell EM, Graus F, Lopez-Guillermo A, Lewis SA, Villa S, Verger E, Petit J (2004) Primary non-Hodgkin’s lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors. Int J Radiat Oncol Biol Phys 59:501–508CrossRefPubMed

25.

Sopittapan T, Tunthanathip T, Kaewborisutsakul A (2020) Outcome and Prognostic Factors of Primary Central Nervous System Lymphoma in Southern Thailand. Asian J Neurosurg 15:560–565. https://doi.org/10.4103/ajns.AJNS_208_20CrossRefPubMedPubMedCentral

26.

Thiel E, Korfel A, Martus P, Kanz L, Griesinger F, Rauch M, Röth A, Hertenstein B, von Toll T, Hundsberger T, Mergenthaler H-G, Leithäuser M, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Plasswilm L, Nägele T, Pietsch T, Bamberg M, Weller M (2010) High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol 11:1036–1047. https://doi.org/10.1016/S1470-2045(10)70229-1CrossRefPubMed

27.

Hoang-Xuan K, Taillandier L, Chinot O, Soubeyran P, Bogdhan U, Hildebrand J, Frenay M, De Beule N, Delattre JY, Baron B (2003) Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol 21:2726–2731CrossRefPubMed

28.

Manickam Gurusamy V, Raveendran Divakar S, Halsnad Chandramouli S, Kunheri B, Hussain Al-Abdulla H, Shaikh G, Chaudary Apsani R, Riyaz Poolakundan M, Caparrotti P, Wafiq Hammoud R, Al-Hammadi N (2023) The role of radiotherapy in newly diagnosed primary CNS lymphoma: A descriptive review and a pragmatic approach to clinical practice. Clin Transl Radiat Oncol 39:100559. https://doi.org/10.1016/j.ctro.2022.12.002CrossRefPubMed

29.

Ferreri AJM, Holdhoff M, Nayak L, Rubenstein JL (2019) Evolving Treatments for Primary Central Nervous System Lymphoma. Am Soc Clin Oncol Educ Book 39:454–466. https://doi.org/10.1200/EDBK_242547CrossRefPubMed

30.

Van Dijck R, Doorduijn JK, Bromberg JEC (2021) The Role of Rituximab in the Treatment of Primary Central Nervous System Lymphoma. Cancers (Basel) 13. https://doi.org/10.3390/cancers13081920

31.

Grommes C, Tang SS, Wolfe J, Kaley TJ, Daras M, Pentsova EI, Piotrowski AF, Stone J, Lin A, Nolan CP, Manne M, Codega P, Campos C, Viale A, Thomas AA, Berger MF, Hatzoglou V, Reiner AS, Panageas KS, DeAngelis LM, Mellinghoff IK (2019) Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma. Blood 133:436–445. https://doi.org/10.1182/blood-2018-09-875732CrossRefPubMedPubMedCentral

32.

Narita Y, Nagane M, Mishima K, Terui Y, Arakawa Y, Yonezawa H, Asai K, Fukuhara N, Sugiyama K, Shinojima N, Kitagawa J, Aoi A, Nishikawa R (2021) Phase I/II study of tirabrutinib, a second-generation Bruton’s tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma. Neurooncology 23:122–133. https://doi.org/10.1093/neuonc/noaa145CrossRef

33.

Guo Y, Lan X, Chang X, Wang G, Zou D, Su L, Sun W (2021) Ibrutinib in Combination with Rituximab and High-Dose Methotrexate in Newly Diagnosed Primary Central Nervous System Lymphoma Patients. Blood 138:1416–1416. https://doi.org/10.1182/blood-2021-147742CrossRef

34.

Chen F, Pang D, Guo H, Ou Q, Wu X, Jiang X, Wei X, Liu S, Huang L, Liang Z, Zhou D, Li W (2020) Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib-based combination therapy: A real-world experience of off-label ibrutinib use. Cancer Med 9:8676–8684. https://doi.org/10.1002/cam4.3499CrossRefPubMedPubMedCentral

35.

Lv L, Sun X, Wu Y, Cui Q, Chen Y, Liu Y (2021) Efficacy and Safety of Ibrutinib in Central Nervous System Lymphoma: A PRISMA-Compliant Single-Arm Meta-Analysis. Front Oncol 11:707285. https://doi.org/10.3389/fonc.2021.707285CrossRefPubMedPubMedCentral

36.

Marcelis L, Antoranz A, Delsupehe A-M, Biesemans P, Ferreiro JF, Debackere K, Vandenberghe P, Verhoef G, Gheysens O, Cattoretti G, Bosisio FM, Sagaert X, Dierickx D, Tousseyn T (2020) In-depth characterization of the tumor microenvironment in central nervous system lymphoma reveals implications for immune-checkpoint therapy. Cancer Immunol Immunother 69:1751–1766. https://doi.org/10.1007/s00262-020-02575-yCrossRefPubMedPubMedCentral

37.

Judd J, Dulaimi E, Li T, Millenson MM, Borghaei H, Smith MR, Al-Saleem T (2017) Low Level of Blood CD4 + T Cells Is an Independent Predictor of Inferior Progression-free Survival in Diffuse Large B-cell Lymphoma. Clin Lymphoma Myeloma Leuk 17:83–88. https://doi.org/10.1016/j.clml.2016.11.005CrossRefPubMed

38.

Dehghani M, Sharifpour S, Amirghofran Z, Zare HR (2012) Prognostic significance of T cell subsets in peripheral blood of B cell non-Hodgkin’s lymphoma patients. Med Oncol 29:2364–2371. https://doi.org/10.1007/s12032-012-0176-1CrossRefPubMed

39.

Zhang X-Y, Xu J, Zhu H-Y, Wang Y, Wang L, Fan L, Wu Y-J, Li J-Y, Xu W (2016) Negative prognostic impact of low absolute CD4 + T cell counts in peripheral blood in mantle cell lymphoma. Cancer Sci 107:1471–1476. https://doi.org/10.1111/cas.13020CrossRefPubMedPubMedCentral

40.

Zhou H, Zheng C, Huang D-S (2020) A prognostic gene model of immune cell infiltration in diffuse large B-cell lymphoma. PeerJ 8:e9658. https://doi.org/10.7717/peerj.9658CrossRefPubMedPubMedCentral

41.

Lin Z, Ma J, Ma Y, Li Q, Kang H, Zhang M, Chen B, Xia R (2023) Prognostic impact of peripheral natural killer cells in primary central nervous system lymphoma. Front Immunol 14. https://doi.org/10.3389/fimmu.2023.1191033

42.

Hernández-Verdin I, Kirasic E, Wienand K, Mokhtari K, Eimer S, Loiseau H, Rousseau A, Paillassa J, Ahle G, Lerintiu F, Uro-Coste E, Oberic L, Figarella-Branger D, Chinot O, Gauchotte G, Taillandier L, Marolleau JP, Polivka M, Adam C, Ursu R, Schmitt A, Barillot N, Nichelli L, Lozano-Sánchez F, Ibañez-Juliá MJ, Peyre M, Mathon B, Abada Y, Charlotte F, Davi F, Stewart C, de Reyniès A, Choquet S, Soussain C, Houillier C, Chapuy B, Hoang-Xuan K, Alentorn A (2023) Molecular and clinical diversity in primary central nervous system lymphoma. Ann Oncol 34:186–199. https://doi.org/10.1016/j.annonc.2022.11.002CrossRefPubMed

Title: Clinicopathological risk factors for prognosis and therapeutic response of primary central nervous system lymphoma in China: a single-center retrospective analysis of 118 cases
Authors: Ling Duan
Wenhui Guo
Shuo Yin
Gehong Dong
Wenbin Li
Feng Chen
Publication date: 18-12-2024
Publisher: Springer Berlin Heidelberg
Keyword: Lymphoma
Published in: Annals of Hematology / Issue 1/2025
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-024-06147-3

Diagnostic performance of liver stiffness as marker of liver involvement in systemic immunoglobulin light chain (AL) amyloidosis

Open Access
AL Amyloidosis
Research

Comparative safety of different first-line treatments for chronic lymphocytic leukemia/small lymphocytic lymphoma: A systematic review and network meta-analysis

Obinutuzumab
Review

How I diagnose and treat patients in the pre-fibrotic phase of primary myelofibrosis (pre-PMF) - practical approaches of a German expert panel discussion in 2024

Open Access
Primary Myelofibrosis
Research

Folate metabolism in myelofibrosis: a missing key?

Open Access
Folic Acid
Review

The impact of Mycoplasma pneumoniae infection on platelets in children with immune thrombocytopenia: a real-world study from China

Whole exome sequencing analysis of a patient with myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions with ETV6::LYN fusion gene

T-Lymphoblastic Lymphoma
Case Report

Elevate your expertise in aplastic anemia (Link opens in a new window)

Aplastic Anemia
Independent Medical Education

Transform the way you care for your patients with aplastic anemia with our 3-module series using real-world case studies and expert insights. Discover why early diagnosis matters, explore the benefits and risks of current treatments, and develop tailored approaches for complex cases.

Supported by:

Pfizer

Developed by: Springer Healthcare IME

Learn more

Keynote series | Spotlight on menopause

Menopause
Video Series

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.

Prof. Martha Hickey

Dr. Claudia Barth

Dr. Samar El Khoudary

Developed by: Springer Medicine

Watch now

Podcast | Sexual health in older age

Springer Medicine

Clinicopathological risk factors for prognosis and therapeutic response of primary central nervous system lymphoma in China: a single-center retrospective analysis of 118 cases

Abstract

Other articles of this Issue 1/2025

Diagnostic performance of liver stiffness as marker of liver involvement in systemic immunoglobulin light chain (AL) amyloidosis

Comparative safety of different first-line treatments for chronic lymphocytic leukemia/small lymphocytic lymphoma: A systematic review and network meta-analysis

How I diagnose and treat patients in the pre-fibrotic phase of primary myelofibrosis (pre-PMF) - practical approaches of a German expert panel discussion in 2024

Folate metabolism in myelofibrosis: a missing key?

The impact of Mycoplasma pneumoniae infection on platelets in children with immune thrombocytopenia: a real-world study from China

Whole exome sequencing analysis of a patient with myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions with ETV6::LYN fusion gene

Elevate your expertise in aplastic anemia (Link opens in a new window)

Keynote series | Spotlight on menopause

Podcast | Sexual health in older age

Springer Medicine

Abstract

Please log in to get access to this content